Abstract
Background Lung-targeted anti-inflammatory therapy could potentially improve outcomes in patients with COVID-19. The novel inhaled pan-Janus kinase (JAK) inhibitor TD-0903 was designed to optimise delivery to the lungs while limiting systemic exposure. Here, we report results from the completed Part 1 of a 2-part phase 2 trial (NCT04402866) in hospitalised patients with severe COVID-19.
Methods Part 1 explored 3 doses of TD-0903 (1, 3, and 10 mg once-daily for 7 days) and placebo in a randomised, double-blind, ascending-dose study. Each dose cohort comprised 8 hospitalized patients (6:2 TD-0903:placebo) with PCR-confirmed COVID-19 requiring supplemental oxygen and receiving background standard-of-care therapy. Key objectives included safety and tolerability, pharmacokinetics, and oxygen saturation/fraction of inspired oxygen ratio; clinical outcomes were also explored. Data were summarised as descriptive statistics.
Results Twenty-five patients were randomised to receive TD-0903 1 mg (n = 6), 3 mg (n = 7), 10 mg (n = 6), or placebo (n = 6). Almost all patients (92%) received background dexamethasone; 3 (12%) received remdesivir. TD-0903 was generally well tolerated with no drug-related serious adverse events. Low plasma concentrations of TD-0903 were observed at all doses. Clinically favourable numerical trends in patients receiving TD-0903 vs placebo included improved 8-point clinical status, shortened hospitalisation, improved oxygenation, and fewer deaths.
Conclusions In Part 1 of this phase 2 trial, the novel inhaled JAK inhibitor TD-0903 showed potential for treatment of patients with severe COVID-19. TD-0903 3 mg is being evaluated in Part 2 of the randomised, double-blind, parallel-group trial in 198 hospitalized patients with COVID-19.
Competing Interest Statement
DS reports personal fees from Theravance Biopharma during the conduct of the study; and personal fees from AstraZeneca; Boehringer Ingelheim; Chiesi; Cipla; Genentech; GlaxoSmithKline; Glenmark; Menarini; Mundipharma; Novartis; Peptinnovate; Pfizer; Pulmatrix; Theravance Biopharma; and Verona outside this work. MB is an employee of Arensia Exploratory Medicine SRL. VM is an employee of Arensia Exploratory Medicine, LLC. RL reports an independent grant from Vertex Pharmaceuticals for an investigator-initiated study on gastro-oesophageal reflux, honoraria from the Manchester Adult CF Centre for speaking at a conference, and travel awards from the European CF Society and British Thoracic Society. EJM, DLB, NDP, JW, EK, DAL, EYW, TN, and RS are employees of Theravance Biopharma US, Inc., and shareholders of Theravance Biopharma, Inc. GDC is a former employee of Theravance Biopharma US, Inc., and owns shares in Theravance Biopharma, Inc. AW reports fees from Theravance Biopharma, Inc., for consulting on the study design. BH is an employee of Theravance Biopharma UK Limited and shareholder of Theravance Biopharma, Inc.
Clinical Trial
NCT04402866
Funding Statement
The study was funded by Theravance Biopharma Ireland Limited. Medical writing and editorial support were provided by Judith M. Phillips, DVM, PhD, of AlphaBioCom, LLC, and funded by Theravance Biopharma US, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by independent ethics committees at each site: National Committee for Ethical Expertise of Clinical Trial Address: MD 2009 Chisinau City, 3 A Cosmescu Street, Republic of Moldova Decision: Approved North West - Greater Manchester Central Research Ethics Committee 3rd Floor Barlow House 4 Minshull Street Manchester M1 3DZ Decision: Approved Local Ethics Committee at Municipal Non-Profit Enterprise "Brovary multidisciplinary clinical hospital" of Brovary district council of Kyiv region and Brovary City Council of Kyiv region; Address: 14, Shevchenko street, Brovary, Kyiv Region, 07400, Ukraine Decision: Approved Ethics Committee at Municipal Non-Profit Enterprise "Oleksandrivska Kyiv city clinical hospital" of the executive body of the Kyiv City Council (Kyiv City State Administration) Address: 39/1, Shovkovychna St, Kyiv, 01601 Ukraine Decision: Approved
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Theravance Biopharma (and its affiliates) will not be sharing individual de-identified participant data or other relevant study documents.
